HTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients

Pharmacogenomics

Volumn 11, Issue 5, 2010, Pages 685-692

  Liu, Bao Cheng ^a,b,c   Zhang, Jing ^a,b,c   Wang, Lei ^a,b,c   Li, Xing Wang ^a,b,c   Wang, Yang ^a,b,c   Wei, Zhi Yun ^a,b,c   Ji, Jue ^a,b,c   Yang, Feng Ping ^a,b,c   Wan, Chun Ling ^a,b,c   Xu, Yi Feng ^d   Feng, Guo Yin ^d   He, Lin ^a,b,c   He, Guang ^a,b,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^d SHANGHAI MENTAL HEALTH CENTER   (China)

Author keywords

HTR2C; Pharmacogenomics; Risperidone; Schizophrenia; Treatment response

Indexed keywords

RISPERIDONE; SEROTONIN 2C RECEPTOR;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PROMOTER REGION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BRIEF PSYCHIATRIC RATING SCALE; FEMALE; GENE DELETION; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; REGULATORY SEQUENCES, NUCLEIC ACID; RISPERIDONE;

EID: 77951586067     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.23     Document Type: Article

References (42)

1. Cardno AG, Gottesman II: Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics. Am. J. Med. Genet. 97, 12-17 (2000).
2. Tsuang M: Schizophrenia: genes and environment. Biol. Psychiatry 47, 210-220 (2000).
3. Leysen JE, Gommeren W, Eens A et al.: Biochemical profle of risperidone. a new antipsychotic. J. Pharmacol. Exp. Ther. 247, 661-670 (1988).
4. Kane JM: Schizophrenia. N. Engl. J. Med. 334, 34-41 (1996).
5. Veenstra-VanderWeele J, Anderson GM, Cook EH Jr: Pharmacogenetics and the serotonin system: initial studies and future directions. Eur. J. Pharmacol. 410, 165-181 (2000).
6. Arranz MJ, de Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 12, 707-747 (2007).
7. Lucki I: The spectrum of behaviors infuenced by serotonin. Biol. Psychiatry 44, 151-162 (1998).
8. Meltzer HY: The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21, S106-S115 (1999).
9. Kaufman MJ, Hartig PR, Hoffman BJ: Serotonin 5-HT2C receptor stimulates cyclic GMP formation in choroid plexus. J. Neurochem. 64, 199-205 (1995).
10. Pandey SC, Lumeng L, Li TK: Serotonin2C receptors and serotonin2C receptor-mediated phosphoinositide hydrolysis in the brain of alcohol-preferring and alcohol-nonpreferring rats. Alcohol Clin. Exp. Res. 20, 1038-1042 (1996).
11. Moreau JL, Bos M, Jenck F, Martin JR, Mortas P, Wichmann J: 5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur. Neuropsychopharmacol. 6, 169-175 (1996).
12. Nakae A, Nakai K, Tanaka T et al.: The role of RNA editing of the serotonin 2C receptor in a rat model of oro-facial neuropathic pain. Eur. J. Neurosci. 27, 2373-2379 (2008).
13. Buckland PR, Hoogendoorn B, Guy CA, Smith SK, Coleman SL, O'Donovan MC: Low gene expression conferred by association of an allele of the 5-HT2C receptor gene with antipsychotic-induced weight gain. Am. J. Psychiatry 162, 613-615 (2005).
14. Segman RH, Heresco-Levy U, Finkel B et al.: Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl.) 152, 408-413 (2000).
15. Wilffert B, Al Hadithy AF, Sing VJ et al.: The role of dopamine D3. 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment. J. Psychopharmacol. 23(6), 652-659 (2009).
16. Mulder H, Cohen D, Scheffer H et al.: HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J. Clin. Psychopharmacol. 29, 16-20 (2009).
17. Mulder H, Franke B, van der-Beek van der AA et al.: The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J. Clin. Psychopharmacol. 27, 338-343 (2007).
18. Kuzman MR, Medved V, Bozina N, Hotujac L, Sain I, Bilusic H: The infuence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res. 160, 308-315 (2008).
19. Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z: Pharmacogenetics of treatment in frst-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur. Neuropsychopharmacol. 15, 143-151 (2005).
20. Ikeda M, Yamanouchi Y, Kinoshita Y et al.: Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in frst-episode schizophrenia. Pharmacogenomics 9, 1437-1443 (2008).
21. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Press, Washington, DC, USA (1994).
22. Wang L, Yu L, Zhang AP et al.: Serum prolactin levels. plasma risperidone levels. polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J. Psychopharmacol. 21, 837-842 (2007).
23. Xuan J, Zhao X, He G et al.: Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology 33, 305-311 (2008).
24. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol. Rep. 10, 799-812 (1962).
25. Correia C T, Almeida JP, Santos PE et al.: Pharmacogenetics of risperidone therapy in autism: association ana lysis of eight candidate genes with drug effcacy and adverse drug reactions. Pharmacogenomics J. (2009) (Epub ahead of print).
26. Rousset F, Raymond M: Testing heterozygote excess and defciency. Genetics 140, 1413-1419 (1995).
27. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: ana lysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265 (2005).
28. Shi Y Y, He L: SHEsis. a powerful software platform for analyses of linkage disequilibrium. haplotype construction. and genetic association at polymorphism loci. Cell Res. 15, 97-98 (2005).
29. Gupta M, Chauhan C, Bhatnagar P et al.: Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms. Pharmacogenomics 10(3), 385-397 (2009).
30. Lieberman JA, Mailman RB, Duncan G et al.: Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiatry 44, 1099-1117 (1998).
31. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K: Identifcation of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 43, 373-376 (2000).
32. Godlewska BR, Olajossy-Hilkesberger L, Ciwoniuk M et al.: Olanzapine-induced weight gain is associated with the-759C/T and-697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J. 9, 234-241 (2009).
33. Sodhi MS, Arranz MJ, Curtis D et al.: Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 7, 169-172 (1995).
34. Alenius M, Wadelius M, Dahl ML et al.: Gene polymorphism infuencing treatment response in psychotic patients in a naturalistic setting. J. Psychiatr. Res. 42, 884-893 (2008).
35. Masellis M, Basile V, Meltzer HY et al.: Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19, 123-132 (1998).
36. Hong CJ, Lin CH, Yu Y W, Yang KH, Tsai SJ: Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics 11, 265-268 (2001).
37. Hill MJ, Reynolds GP: 5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity. Brain Res. 1149, 14-17 (2007).
38. McCarthy S, Mottagui-Tabar S, Mizuno Y et al.: Complex HTR2C linkage disequilibrium and promoter associations with body mass index and serum leptin. Hum. Genet. 117, 545-557 (2005).
39. Basta-Kaim A, Budziszewska B, Jaworska-Feil L et al.: Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology 31, 853-865 (2006).
40. White FJ, Wang RY: Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221, 1054-1057 (1983).
41. Williams R: Optimal dosing with risperidone: updated recommendations. J. Clin. Psychiatry 62, 282-289 (2001).
42. Rothman KJ: No adjustments are needed for multiple comparisons. Epidemiology 1, 43-46 (1990).